📧 Communication
ProcessCommunication Details
From
Generic drug companies (e.g., Mylan)
Linked to Generic drug companies (e.g., Mylan)
To
Celgene
Celgene
Subject
Request for drug samples for generic development
Message Content
The document describes a pattern of communication where Celgene would refuse to distribute drug samples, citing REMS, and demand written confirmation from the F.D.A. After generic companies provided this, Celgene would then request more 'laborious, irrelevant and time consuming' information to further delay the process.
📄 Source Document
HOUSE_OVERSIGHT_028420.jpg
ESTATE Collection
Document Summary
The document is JSON code describing an article about the pharmaceutical company Celgene. The article alleges that Celgene used a federal safety program (REMS) to block generic competition for its drugs, Revlimid and Thalomid, leading to lawsuits from companies like Mylan. The text also mentions a patient paying high costs and a professor criticizing Celgene's actions.
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein communication